Cidara Therapeutics Inc

Cidara Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for patients with cancers and other serious diseases. Its product portfolio includes rezafungin acetate, a novel echinocandin-class antifungal for treating and preventing invasive fungal infections such as candidemia and invasive candidiasis, which are associated with high mortality rates. The company also develops the Cloudbreak platform for novel drug-Fc conjugates, including CD388, a potent antiviral in Phase 1 and Phase 2a clinical trials for universal prevention and treatment of seasonal and pandemic influenza. Formerly known as K2 Therapeutics, Inc., it changed its name to Cidara Therapeutics, Inc. in July 2014, was incorporated in 2012, and is based in San Diego, California.